At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 160 enrolled
Drug / intervention
Placebo oral capsule +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate the Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder
In Brief
A Phase 2 clinical trial evaluating Placebo oral capsule and NYX-783 for Post-Traumatic Stress Disorder. Completed, enrolled 160 participants across 37 sites.
Detailed Summary
To evaluate the safety, tolerability, and response profile of NYX-783 in a Post-Traumatic Stress Disorder population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost-Traumatic Stress Disorder
CountriesUnited States
CollaboratorsPremier Research, Massachusetts General Hospital
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartJan 2019
First PostedAug 2019
Primary CompletionAug 2020
TodayJul 2026
First PostedAug 5, 2019
Enrollment StartJan 25, 2019
Primary CompletionAug 5, 2020
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 6.9 years ago
Interventions
Placebo oral capsuledrug
Matching placebo capsules.
NYX-783drug
NYX-783 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).